Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Nature's Sunshine Products Q1 2026 Earnings Call - Digital Autoship Fuels Record Sales Growth
Nature's Sunshine delivered a record first quarter with sales rising 9% to $122.9 million and adjusted EBITDA jumping 33% to $14.6 million. The growth was led by a 42% surge in digital sales, driven b...
- Record Q1 2026 net sales of $122.9 million, up 9% year-over-year, marking the strongest first quarter in company history.
- Adjusted EBITDA surged 33% to $14.6 million, driven by sales growth and an 116 basis point expansion in gross margin to 73.2%.
- Digital sales jumped 42%, fueled by a 60% increase in new customers and robust adoption of the autoship subscription program, which now represents 48% of digital revenue.
- +7 more takeaways
CytomX Therapeutics Q1 2026 Earnings Call - Varseta-M Hits 32% Response Rate in Colorectal Cancer, Cash Runway Extends to 2028
CytomX Therapeutics delivered a strong start to 2026, anchored by clinical momentum in its lead asset, Varseta-M, a first-in-class EpCAM-directed antibody drug conjugate for metastatic colorectal canc...
- Varseta-M demonstrates transformative efficacy in late-line metastatic colorectal cancer, with a confirmed overall response rate of 20% to 32% and 7 months of median progression-free survival.
- Dose optimization enrollment is complete with 40 patients across 8.6 and 10 mg/kg doses, bringing total Phase I enrollment to 113 patients.
- CytomX aims to advance Varseta-M into a registrational study in late-line CRC in the first half of 2027, with a comprehensive Phase I data update expected in the second half of 2026.
- +7 more takeaways
Consensus Cloud Solutions Q1 2026 Earnings Call - Corporate Channel Accelerates Past 8% Growth
Consensus Cloud Solutions delivered a Q1 2026 quarter that validated its strategic pivot toward high-value corporate accounts, with corporate revenue surging 8.2% year-over-year to a record $58.7 mill...
- Corporate channel revenue hit a record $58.7 million, up 8.2% year-over-year, marking the strongest growth rate since Q4 2022 and validating the company’s strategic focus on high-value enterprise accounts.
- This marks the second consecutive quarter of year-over-year growth in all four key financial metrics: revenue, adjusted EBITDA, non-GAAP EPS, and free cash flow.
- Net revenue retention (NRR) rose to 102%, a 76 basis point sequential improvement, driven by deeper enterprise adoption and increased data volume routing through the platform.
- +9 more takeaways
Nektar Therapeutics Q1 2026 Earnings Call - REZPEG Advances to Phase III with $1B+ Cash Runway
Nektar Therapeutics is moving its lead candidate, REZPEG, into Phase III trials for atopic dermatitis (ZENITH-AD program) starting in July 2026, with first data expected mid-2028 and a BLA submission ...
- 1. Nektar Therapeutics is initiating the ZENITH-AD Phase III program for atopic dermatitis in July 2026, with first data expected mid-2028 and a BLA submission targeted for 2029.
- 2. The company plans to launch a Phase III study for alopecia areata in early 2027, aiming to add a second indication to the same BLA submission.
- 3. REZPEG’s novel regulatory T-cell mechanism shows deepening efficacy over time, with potential for monthly or quarterly maintenance dosing in atopic dermatitis.
- +9 more takeaways
SoundHound AI Q1 2026 Earnings Call - Accelerating Growth with LivePerson Acquisition and OASYS Platform Launch
SoundHound AI delivered strong Q1 2026 results with 52% year-over-year revenue growth to $44.2 million, driven by enterprise momentum and a 50%+ organic growth rate in its automotive and IoT segments....
- Q1 2026 revenue reached $44.2 million, up 52% year-over-year, with 50%+ organic growth excluding acquisitions.
- Management announced the acquisition of LivePerson, targeting a combined $500 million revenue opportunity from existing customer bases.
- OASYS platform launched, enabling AI to autonomously build, deploy, and refine agents across multiple channels.
- +12 more takeaways
Eastman Kodak Q1 2026 Earnings Call - Third Consecutive Quarter of Growth as Film Resurgence and Pharma Expansion Drive Momentum
Eastman Kodak delivered its third consecutive quarter of year-over-year growth in Q1 2026, posting $265 million in revenue and $15 million in operational EBITDA. The company is capitalizing on a tangi...
- Consolidated revenue grew 7% year-over-year to $265 million, marking the third consecutive quarter of top-line expansion despite persistent inflationary pressures.
- Operational EBITDA surged to $15 million, a 650% increase from $2 million in the prior-year quarter, driven by improved pricing and operational discipline.
- Gross profit percentage expanded by 300 basis points to 22%, up from 19% in Q1 2025, reflecting successful cost management and product mix optimization.
- +9 more takeaways
Callaway Golf Company Q1 2026 Earnings Call - Tariff Relief and Margin Expansion Drive Raised Guidance
Callaway Golf delivered a strong Q1 2026 beat, with revenue up 9% to $688 million and adjusted EBITDA surging 31% to $164 million. The company raised full-year guidance, citing $25 million in tariff s...
- Revenue grew 9% year-over-year to $688 million, outpacing market growth and beating guidance by $38 million.
- Adjusted EBITDA surged 31% to $164 million, driven by higher sales, margin improvements, and tariff savings.
- Gross margins expanded 260 basis points to 47.7%, despite $18 million in incremental tariff expenses.
- +7 more takeaways
CarParts.com Q1 2026 Earnings Call - First Positive Adjusted EBITDA Signals Execution of Leaner Model
CarParts.com delivered its first positive adjusted EBITDA since Q1 2024, marking a $7 million year-over-year swing and validating a five-quarter restructuring effort focused on advertising efficiency,...
- CarParts.com reported its first positive adjusted EBITDA since Q1 2024, posting a $585,000 profit compared to a $6.2 million loss a year ago, representing a nearly $7 million year-over-year improvement.
- Net sales declined 10% year-over-year to $132 million, primarily due to a deliberate shift toward higher-intent, higher-return customers and real-time pricing adjustments to offset freight cost headwinds.
- Gross margin expanded 40 basis points to 32.5%, driven by pricing discipline and favorable product mix, even as the company manages growth through contribution margin dollars rather than reported gross margin percentages.
- +9 more takeaways
Arlo Technologies Q1 2026 Earnings Call - Record Revenue and Margin Expansion Outpace SaaS Peers
Arlo Technologies reported a record Q1 2026, delivering $150.4 million in revenue and $0.28 in non-GAAP EPS, both well above guidance. The results were fueled by a 29% year-over-year surge in annual r...
- Record Q1 2026 revenue of $150.4 million, up 26% year-over-year, and non-GAAP EPS of $0.28, up 86% year-over-year, both significantly exceeding guidance.
- Annual recurring revenue (ARR) surged 29% to $357 million, driven by 318,000 new paid accounts and ARPU growth of 16% to $15.60.
- Consolidated non-GAAP gross margins reached a record 50%, a 460 basis point improvement, with subscriptions and services gross margins hitting 85.4%.
- +7 more takeaways
Monster Beverage Corporation Q1 2026 Earnings Call - Sales Cross $2B Threshold for First Time with Double-Digit Growth Across All Regions
Monster Beverage Corporation delivered a historic first quarter of 2026, with net sales surpassing $2 billion for the first time, driven by double-digit growth across all geographic regions and sustai...
- Net sales reached $2.35 billion in Q1 2026, marking the first time the company has crossed the $2 billion threshold in a fiscal first quarter, representing 26.9% year-over-year growth.
- Monster Energy Drinks segment sales grew 27.6% to $2.19 billion, while Strategic Brands increased 28.9% to $126.7 million, offsetting a 5.9% decline in Alcohol Brands to $32.7 million.
- International net sales surged 44.9% to $1.06 billion, now representing approximately 45% of total sales, with EMEA up 52.5% and APAC up 39.7% in dollar terms.
- +7 more takeaways